Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

High pre-harvest donor Foxp3 mRNA level predicts late relapse of acute lymphoblastic leukaemia after haematopoietic stem cell transplantation

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Healthcare Resource Utilization in Patients with Myeloproliferative Neoplasms: A Danish Nationwide Matched Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early- and late-onset posttransplant lymphoproliferative disorders among adult kidney and liver transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A saturated map of common genetic variants associated with human height

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Higher recipient pre-transplant FOXP3 mRNA expression is associated with acute leukaemia relapse after HSCT

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: The curative effect of allogeneic haematopoietic stem cell transplantation (HSCT) for acute leukaemia is due in part to the donor T cell-mediated graft-versus-leukaemia immune reaction (GvL). Several studies have suggested that donor CD25+CD4+Foxp3+ regulator T cells (Tregs) may decrease graft-versus-host disease (GvHD) without abrogating GVL. This notion may need modification in acute lymphoblastic leukaemia (ALL).

METHODS: Foxp3 mRNA level was measured by qPCR in pre-harvest donor blood CD4+ T cells. The study comprised 45 patients with ALL in 1st or 2nd CR who received myeloablative HSCT using T-replete bone marrow grafts.

RESULTS: Relapse occurred in 17 patients median 363 days after HSCT. The relapse risk was estimated by Cox univariate and multivariate proportional hazard regression. The proportionality assumption was met by analysing the pre-harvest donor Foxp3 mRNA level as a time-dependent covariate. Early relapse was not modified by the Foxp3 mRNA level. However, a higher Foxp3 mRNA level was associated with a significantly increased relapse risk after day 363 after transplantation, compatible with inhibition of GvL. In contrast, a higher pre-harvest donor CD4+ T cell concentration was associated with reduced relapse risk.

CONCLUSION: A higher pre-harvest donor Foxp3 mRNA level may be predictive of late ALL relapse after HSCT.

Original languageEnglish
JournalEuropean Journal of Haematology
Volume106
Issue number5
Pages (from-to)643-653
ISSN0902-4441
DOIs
Publication statusPublished - May 2021

Bibliographical note

© 2021 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.

    Research areas

  • acute lymphoblastic leukaemia, Foxp3, haematopoietic stem cell transplantation, regulatory T cells

ID: 62112730